Back

Trastuzumab cardiotoxicity: incidence, risk factors and the role of cardiac monitoring

26 August 2017 (00:00 - 00:00)
Organised by:
Congress Presentation Part of: Poster session 4 - Chronic heart failure (CHF) Cardiotoxicity of drugs ESC Premium Access ESC Congress 2017

About the speaker

Photo
Doctor Mohammed Alawami

Central Manchester University Hospitals NHS Foundation Trust, Manchester (United Kingdom of Great Britain & Northern Ireland)

28 More presentations in this session

Presentation thumbnail
Myocardial perfusion in diabetic patients with acute myocardial infarction and long term risk of heart failure development
Doctor A. Tomasik (Zabrze, PL)
Abstract Slides
Presentation thumbnail
In vivo evidence of chronic myocardial inflammation in ischaemic cardiomyopathy using USPIO enhanced cardiovascular magnetic resonance
Doctor J. Lagan (Chester, GB)
Abstract Slides
Presentation thumbnail
Pattern of myocardial 99mTc-HMDP uptake and impact on myocardial function in patients with transthyretin amyloidosis
Miss S. Brun (Toulouse, FR)
Abstract Slides
Presentation thumbnail
Aldehyde dehydrogenase 2 ameliorates cyclophosphamide-induced cardiotoxicity through detoxification of toxic aldehydes and suppression of cell death
Doctor J. Wang (Jinan, CN)
Abstract Slides
Presentation thumbnail
A new echo-Doppler index to predict early myocardial toxicity secondary to chemotheraphy
Professor S. Baratta (Pilar, AR)
Abstract Slides

Access the full session

Session thumbnail
Poster session 4 - Chronic heart failure (CHF)

The Event

Event poster

ESC Congress 2017

26 August - 30 August 2017

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources